Current Myeloma Treatment Paradigm: 10-15 Months of Treatment, Five Years of Survival.

The article reports on the outcomes of multiple myeloma study concerning the profile of the duration of on-and off-drug periods during the course of the patient's disease. The profile suggests that the overall survival of myeloma patients is in the range of 5.0-5.25 years from first treatment. Meanwhile, one of the benefits of newer agents such as Revlimid is that their improved side effect profile will allow longer duration of dosing, and longer progression-free and overall survival.